Axial Stem Cell Production via Wnt Pathway Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing human axial stem cells are laborious and result in transient progenitors contaminated with other cell types, making it inaccessible to derive axial stem cells from human embryos.

Innovation Solution

A method involving pluripotent stem cells, where the Wnt/β-catenin signaling pathway is activated using CHIR99021 inhibitor, followed by serial passaging in RPMI 1640 medium with B27 supplement, to derive axial stem cells expressing SOX2, TBXT, and MIXL1, and not expressing Pax6, capable of differentiating into motor neurons, bone, and cartilage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If current methods are used to produce human axial stem cells, then some progenitors can be obtained, but the production process is laborious and the cells are contaminated with other cell types

Engineering Contradiction:

Improvepurity of axial stem cellsVSAvoidcomplexity of production method

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent changes the biochemical parameters of the culture system by introducing specific small molecules (CHIR99021 to activate Wnt/β-catenin pathway, SB431542 to inhibit TGF-β pathway) to transform pluripotent stem cells into axial stem cells with high purity, avoiding laborious manual separation methods

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses small molecule compounds as intermediaries to mediate the differentiation process: CHIR99021 acts as a mediator to activate Wnt signaling, and SB431542 acts as a mediator to inhibit TGF-β signaling, enabling precise control over cell fate and achieving pure axial stem cell populations

Inventive Principle:

Principle #24Intermediary (Mediator)

2Manufacturing precision

If axial stem cells are derived from human embryos, then pure axial stem cells can be obtained, but the process is inaccessible and ethically problematic

Engineering Contradiction:

Improvepurity of axial stem cellsVSAvoidaccessibility of derivation method

Core Design Contradiction:

Manufacturing precisionVSAdaptability or versatility

Solution Approach 1:

The patent uses induced pluripotent stem cells (iPSCs) as a copy or alternative to embryonic stem cells, achieving the same axial stem cell derivation goal without the ethical and accessibility issues of embryo destruction. The iPSCs are reprogrammed from adult cells to mimic the pluripotent state

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent changes the source material parameter from human embryos to induced pluripotent stem cells, fundamentally altering the accessibility and ethical profile of the method while maintaining the ability to derive pure axial stem cells through controlled differentiation

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If pluripotent stem cells are used, then indefinitely renewing cells can be obtained, but the cells may form teratomas and lack region-specific differentiation

Engineering Contradiction:

Improveself-renewal capabilityVSAvoidsafety and specificity of differentiation

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent changes the differentiation state parameter by using sequential small molecule treatments: first CHIR99021 to induce primitive streak formation, then maintenance with CHIR99021 and SB431542 to preserve axial progenitor identity, resulting in cells that are indefinitely renewable but committed to axial lineages only

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent extracts or removes the pluripotency program by downregulating pluripotent markers (OCT4, NANOG, SOX2) through controlled differentiation, while retaining self-renewal capability through activation of axial progenitor programs (TBXT, MIXL1, SOX17), thereby eliminating teratoma formation risk

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the production of pure, indefinitely renewing axial stem cells that can differentiate into specific cell types of the axial region, such as motor neurons and bone, with improved purity and reduced spontaneous differentiation, facilitating safer and more cost-effective cellular therapies.

Implementation Method 1

activating the Wnt/β-catenin signaling pathway in said pluripotent stem cells

Methodology Applied

Scientific EffectWnt/β-catenin signaling pathway:

Data Source

PatentUS20230203440A1Axial stem cells, methods of producing and uses thereof

Publication Date: 2023.06.29 HELMHOLTZ ZENT MUENCHEN DEUT FORSCHUNGSZENTRUM FUER GESUNDHEIT & UMWELT (GMBH)

AI summary

The present invention relates to methods of producing axial stem cells (AxSCs) as well to axial stem cells (AxSCs) produced by such methods and uses thereof. The present invention further relates to axial stem cells (AxSCs), wherein said axial stem cells are not pluripotent cells, but are, for example, region-specific multipotent stem cells capable of indefinitely renewing themselves.